Jpmorgan Chase & CO Viridian Therapeutics, Inc.\De Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Jpmorgan Chase & CO holds 304,334 shares of VRDN stock, worth $4.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
304,334
Previous 400,351 23.98%
Holding current value
$4.99 Million
Previous $9.11 Million 35.94%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$17.85 - $25.71 $1.71 Million - $2.47 Million
-96,017 Reduced 23.98%
304,334 $5.83 Million
Q3 2024

Dec 26, 2024
BUY
$12.16 - $23.33 $3.34 Million - $6.41 Million
274,641 Added 218.47%
400,351 $9.11 Million
Q3 2024

Nov 08, 2024
BUY
$12.16 - $23.33 $3.34 Million - $6.41 Million
274,641 Added 218.47%
400,351 $9.11 Million
Q2 2024

Dec 26, 2024
SELL
$11.6 - $17.26 $3.19 Million - $4.74 Million
-274,641 Reduced 68.6%
125,710 $1.64 Million
Q2 2024

Aug 12, 2024
BUY
$11.6 - $17.26 $889,569 - $1.32 Million
76,687 Added 156.43%
125,710 $1.64 Million
Q1 2024

Dec 26, 2024
SELL
$17.09 - $23.82 $6 Million - $8.37 Million
-351,328 Reduced 87.75%
49,023 $858,000
Q1 2024

May 10, 2024
SELL
$17.09 - $23.82 $135,267 - $188,535
-7,915 Reduced 13.9%
49,023 $858,000
Q4 2023

Dec 26, 2024
SELL
$11.12 - $22.5 $3.82 Million - $7.73 Million
-343,413 Reduced 85.78%
56,938 $1.24 Million
Q4 2023

Feb 12, 2024
BUY
$11.12 - $22.5 $66,897 - $135,360
6,016 Added 11.81%
56,938 $1.24 Million
Q3 2023

Nov 14, 2023
SELL
$15.16 - $24.7 $137,198 - $223,535
-9,050 Reduced 15.09%
50,922 $781,000
Q2 2023

Aug 11, 2023
BUY
$22.57 - $29.67 $239,129 - $314,353
10,595 Added 21.46%
59,972 $1.43 Million
Q1 2023

May 18, 2023
BUY
$25.04 - $37.6 $1.23 Million - $1.84 Million
48,998 Added 12928.23%
49,377 $1.26 Million
Q1 2023

May 11, 2023
SELL
$25.04 - $37.6 $4.31 Million - $6.47 Million
-171,980 Reduced 99.78%
379 $9,000
Q4 2022

Feb 13, 2023
BUY
$18.78 - $29.74 $1.94 Million - $3.07 Million
103,101 Added 148.87%
172,359 $5.03 Million
Q3 2022

Nov 14, 2022
BUY
$10.7 - $25.5 $544,833 - $1.3 Million
50,919 Added 277.65%
69,258 $1.42 Million
Q2 2022

Aug 11, 2022
SELL
$9.55 - $19.0 $3,122 - $6,213
-327 Reduced 1.75%
18,339 $213,000
Q1 2022

May 11, 2022
BUY
$16.79 - $20.88 $94,578 - $117,617
5,633 Added 43.22%
18,666 $345,000
Q4 2021

Feb 10, 2022
BUY
$15.65 - $21.5 $203,966 - $280,209
13,033 New
13,033 $258,000

Others Institutions Holding VRDN

# of Institutions
203
Shares Held
81.6M
Call Options Held
502K
Put Options Held
870K
View Full List

About Viridian Therapeutics, Inc.\DE

VRDN Quotes by TradingView
  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $654M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email